Jazz Pharmaceuticals Gets European Commission OK for Enrylaze
Provided by
Dow Jones
By Ben Glickman
Jazz Pharmaceuticals on Thursday said it had received market authorization from the European Commission for its treatment for certain types of leukemia and lymphoma.
The Dublin-based pharmaceutical company said that Enrylaze could now be used as a component of a multi-agent chemotherapeutic regiment in the treatment of acute lymphoblastic leukemia and lymphoblastic lymphoma.
Enrylaze is currently approved under the name Rylaze in the U.S. and Canada.
The approval from the European Commission was based on Phase 2/3 trial data.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
September 21, 2023 18:05 ET (22:05 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
These Stocks Are (Still) Powering the Bull Market
-
5 Undervalued Energy Stocks to Play the AI Data Center Demand Boom
-
After Earnings, Is Lowe’s Stock a Buy, Sell, or Fairly Valued?
-
5 Stocks With the Largest Fair Value Estimate Cuts After Q1 Earnings
-
10 Stocks With the Largest Fair Value Estimate Increases After Q1 Earnings
-
Markets Brief: Inflation Back in the Spotlight
-
AI Is Booming, but Consumer Spending Is Slowing. Which Will Prevail in the Stock Market?
-
What’s Happening In the Markets This Week
-
3 Dividend Stocks for June 2024
-
After Earnings, Is Alibaba Stock a Buy, Sell, or Fairly Valued?
-
MongoDB Earnings: Slashing Valuation as Execution and Macro to Blame for Lower Guidance
-
Marvell Earnings: We Raise Our Medium-Term AI Forecast and Bring Our Valuation Up to $75
-
Zscaler Earnings: Impressive Traction in Emerging Products Drives Sales Growth for the Quarter
-
Dell Earnings: Raising Valuation on Strong AI, but the Stock Remains Severely Overvalued
-
After Earnings, Is Nvidia Stock a Buy, Sell, or Fairly Valued?
-
The 10 Best Companies to Invest in Now